Please assess the completion status of the following clinical trial:

Trial Title: A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male as determined by a responsible physician, based on a medical evaluation including history, physical examination, vital signs, laboratory tests and 12-lead ECG.~* Between 18 and 50 years of age, inclusive, at the time of signing and dating the informed consent form.~* Body weight ≥70 kg and body mass index (BMI) within the range 18 - 35 kg/m2 (inclusive).~* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.~* Willing and able to comply with the protocol for the duration of the study.~Exclusion Criteria:~* As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unsuitable for the study.~* The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.~* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.~* A positive test for human immunodeficiency virus (HIV) antibody.~* History of migraine.~* History or evidence of abnormal eating behaviour, as observed through the Dutch Eating Behaviour (DEBQ) and SCOFF questionnaires.~* History of excessive alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units. One unit is equivalent to 8 g of alcohol, a half-pint (approximately 240 mL) of beer or 1 measure (25 mL) of spirits or 1 glass (125 mL) of wine.~* Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.~* Has QTc at screening \>450 msec.~* Systolic blood pressure outside the range 85 - 160 mmHg, diastolic blood pressure outside the range 45 - 100 mmHg, and/or heart rate outside the range 40 - 110 bpm.~* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the dosing day in the current study: 90 days, five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or five half-lives (whichever is longer) prior to the dose of study medication, which, in the opinion of the Investigator, may interfere with the study procedures or compromise subject safety.~* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates their participation.~* Where participation in the study would result in donation of blood in excess of 500 mL within 3 months before or after the study.~* Unwilling to abstain from consumption of caffeine- or xanthine- containing products for 24 hours prior to dosing until the post-dose assessment at each treatment level.~* Unwilling to abstain from use of illicit drugs.~* Unwilling to abstain from alcohol for 48 hours prior to dosing until final post-dose assessment at each treatment level.~* Unwilling to abstain from smoking or otherwise consuming tobacco for 24 hours prior to dosing until the post-dose assessment at each treatment level.~* Unwilling to use a condom during sexual activity from first dose until the end of the study.~* Vegans and subjects with milk or wheat intolerance or allergy as reported by the subject.~* Unwillingness or inability to follow the procedures outlined in the protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 2mg PP 1420 (Type: EXPERIMENTAL): PP 1420 single dose, subcutaneous
- 4mg PP 420 (Type: EXPERIMENTAL): PP 1420 single dose, subcutaneous
- 8mg PP 1420 (Type: EXPERIMENTAL): PP 1420 single dose, subcutaneous
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete